Intravascular persistence of hydroxyethyl starch in man
- PMID: 65282
- DOI: 10.1159/000127896
Intravascular persistence of hydroxyethyl starch in man
Abstract
In two groups, each consisting of five healthy volunteers, 7 ml blood/kg body weight were exchanged with equal amount of hydroxyethyl starch (HES) and dextran 60 solutions, respectively. Dextran 60 plasma levels, determined by the anthrone method, were undetectable after 4 weeks. The elimination of HES from the blood, determined by an immunological technique and by the anthrone method, had a very protracted course. Two weeks after infusion the HES plasma concentrations were 9% of the initial value and after 17 weeks they were still above the 1% level. The prolonged intravascular persistence of HES in its commercially available preparation, and the possibility of tissue accumulation after repeated HES infusions were considered undesirable. The hypothesis that HES infusion causes and augmentation of serum alpha-amylase concentrations in man was confirmed. This effect should be borne in mind when HES solutions are given to patients in whom the diagnosis of acute pancreatitis might be considered.
Similar articles
-
Intravascular persistence of hydroxyethyl starch (HES) after serial granulocyte collections using HES in man.Vox Sang. 1980 Oct;39(4):181-5. doi: 10.1111/j.1423-0410.1980.tb01855.x. Vox Sang. 1980. PMID: 6163255
-
Perioperative volume effect of HES 120/0.7 compared with dextran 70 and Ringer acetate.Ann Chir Gynaecol. 1996;85(4):333-9. Ann Chir Gynaecol. 1996. PMID: 9014063 Clinical Trial.
-
[Determination of the plasma elimination of hydroxyethyl starch and dextran using improved analytical methods].Infusionsther Klin Ernahr. 1981 Apr;8(2):88-94. Infusionsther Klin Ernahr. 1981. PMID: 6164643 German. No abstract available.
-
HES 130/0.42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly.Br J Anaesth. 2007 May;98(5):635-44. doi: 10.1093/bja/aem068. Br J Anaesth. 2007. PMID: 17456491 Review.
-
[Volume replacement with hydroxyethyl starch: is there an influence on kidney function?].Anasthesiol Intensivmed Notfallmed Schmerzther. 2004 Feb;39(2):71-7. doi: 10.1055/s-2004-817674. Anasthesiol Intensivmed Notfallmed Schmerzther. 2004. PMID: 14767795 Review. German.
Cited by
-
Clinical pharmacokinetic considerations in the use of plasma expanders.Clin Pharmacokinet. 1987 Feb;12(2):123-35. doi: 10.2165/00003088-198712020-00003. Clin Pharmacokinet. 1987. PMID: 2435442 Review.
-
Pharmacokinetics of hydroxyethyl starch.Clin Pharmacokinet. 2005;44(7):681-99. doi: 10.2165/00003088-200544070-00002. Clin Pharmacokinet. 2005. PMID: 15966753 Review.
-
[The elimination of hydroxyethyl starch 200/0.5, dextran 40 and oxypolygelatine (author's transl)].Klin Wochenschr. 1982 Mar;60(6):293-301. doi: 10.1007/BF01716806. Klin Wochenschr. 1982. PMID: 6176754 German.
-
Urinary excretion kinetics of hydroxyethyl starch 350/0.60 in normovolaemic man.J Clin Pathol. 1981 Apr;34(4):361-5. doi: 10.1136/jcp.34.4.361. J Clin Pathol. 1981. PMID: 6165740 Free PMC article.
-
Adverse reactions to plasma volume expanders.Drug Saf. 1990 Mar-Apr;5(2):86-93. doi: 10.2165/00002018-199005020-00002. Drug Saf. 1990. PMID: 2182051 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources